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Abstract
Background
Control and elimination of human African trypanosomiasis (HAT) can be accelerated
through the use of diagnostic tests that are more accurate and easier to deploy. The goal of
this work was to evaluate the immuno-reactivity of antigens and identify candidates to be
considered for development of a simple serological test for the detection of Trypanosoma
brucei gambiense or T. b. rhodesiense infections, ideally both.
Methodology/Principal Findings
The reactivity of 35 antigens was independently evaluated by slot blot and ELISA against sera
from both T. b. gambiense and T. b. rhodesiense infected patients and controls. The antigens
that were most reactive by both tests to T. b. gambiense sera were the membrane proteins
VSG LiTat 1.3, VSG LiTat 1.5 and ISG64. Reactivity to T. b. rhodesiense sera was highest
with VSG LiTat 1.3, VSG LiTat 1.5 and SRA, although much lower than with T. b. gambiense
samples. The reactivity of all possible combinations of antigens was also calculated. When
the slot blot results of 2 antigens were paired, a VSG LiTat 1.3- ISG75 combination performed
best on T. b. gambiense sera, while a VSG LiTat 1.3-VSG LiTat 1.5 combination was the
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most reactive using ELISA. A combination of SRA and either VSG LiTat 1.3 or VSG LiTat 1.5
had the highest reactivity on T. b. rhodesiense sera according to slot blot, while in ELISA, pair-
ing SRA with either GM6 or VSG LiTat 1.3 yielded the best results.
Conclusions
This study identified antigens that were highly reactive to T. b. gambiense sera, which could
be considered for developing a serological test for gambiense HAT, either individually or in
combination. Antigens with potential for inclusion in a test for T. b. rhodesiense HAT were
also identified, but because their reactivity was comparatively lower, a search for additional
antigens would be required before developing a test for this form of the disease.
Introduction
Human African trypanosomiasis (HAT) is a neglected tropical disease targeted by the World
Health Organization (WHO) for elimination by 2020 [1]. Since the late 1990’s its global inci-
dence has been declining steadily, but it continues to plague impoverished populations in a
number of sub-Saharan African countries. Approximately 70 million people are estimated to
be at risk of contracting the disease, which is generally fatal in the absence of proper diagnosis
and treatment [2]. Two parasite sub-species are responsible for distinct forms of HAT. While
Trypanosoma brucei gambiense causes a chronic disease in central and western Africa, T. b.
rhodesiense causes acute infections in eastern Africa.
Diagnosis of gambiense HAT is routinely performed following algorithms that include
screening to identify suspects, confirmation of disease, and staging to guide the choice of treat-
ment [3]. Screening is an important process, which ensures that relatively complex and
labour-intensive parasitological tests for confirmation are only performed on individuals who
exhibit an immune response to the pathogen. The card agglutination test for trypanosomiasis
(CATT/T.b. gambiense) has been the most widely used screening test for gambiense HAT over
more than three decades. It detects host antibodies using as antigen a freeze dried suspension
of purified, fixed and stained bloodstream form trypanosomes expressing LiTat 1.3 variant
surface glycoprotein (VSG), which is a predominant variant antigen of T. b. gambiense [4].
However, CATT has a number of operational limitations that hinder its large-scale implemen-
tation, especially in basic health facilities in remote areas, including the need for specialized
equipment, electricity and refrigeration. The sensitivity and specificity of CATT have also been
reported to be sub-optimal in a number of settings [5]. To try and address some of these short-
comings, other screening tests have been developed. These include the LATEX/T. b. gambiense
test, which is a card agglutination test similar to CATT but whose antigenic basis is a mixture
of three purified variant surface glycoproteins (LiTat 1.3, 1.5 and 1.6) adsorbed on latex beads
[6]. While further evaluations will be needed, currently available results indicate that the
LATEX/T. b. gambiense test would have a higher specificity but a lower or similar sensitivity to
the CATT test [5]. Immunofluorescence assays and enzyme-linked immunosorbent assay
(ELISA) methods have also been used with success, but the sophisticated equipment that they
require has resulted in their use being limited to reference laboratories [5]. Attempts have also
been made to develop an antigen detection test for gambiense HAT, which would allow a dis-
tinction between past and current infections. These include the card indirect agglutination test
for trypanosomiasis (TrypTect CIATT), which was found to be highly sensitive but whose
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specificity remains uncertain [5,7,8]. The situation is more problematic in countries that are
endemic for rhodesiense HAT, as no screening test is available for this form of the disease.
Thus, developing and introducing new screening tools that would be both simple to use
and highly accurate could play a central role in enhancing control and facilitating elimination
of HAT. The goal of this study was to evaluate the diagnostic potential of antigens supplied by
various research organisations and universities, and identify the most promising ones that
could be used for development of a simple serological test for HAT. The test would ideally be a
lateral-flow rapid diagnostic test (RDT) for screening patients suspected of HAT and popula-
tions living in endemic areas, which could be deployed within various levels of the healthcare
system in HAT endemic countries, including rural, resource-limited settings where the disease
is usually found.
Materials and Methods
Antigens
Candidate antigens were identified based on a literature search and through personal contacts.
A request for access to antigens was sent to the corresponding academic organizations, and
after signature of Material Transfer Agreements with FIND (Foundation for Innovative New
Diagnostics), the antigens were shipped by the different suppliers to FIND where they were
stored at -20˚C. After all antigens were received, they were delivered to the University of
Geneva Hospitals, Switzerland, where they were thawed and transferred into new tubes that
were labelled with identification codes. Subsequently, the antigens, which were now anony-
mous as to function and origin, were shipped to Microcoat Biotechnologie GmbH where the
screening was performed. Microcoat did not have access to any information that could allow
identification of the antigens. Table 1 shows the 35 antigens that were screened in this study,
including their source, supplier and method of production. Two of the antigens were purified
native VSGs obtained from rodent infections, while the rest were purified recombinant pro-
teins expressed in Escherichia coli.
Serum samples
Three rounds of screening were carried out, and for each round a different set of positive
serum samples from T. b. gambiense and T. b. rhodesiense HAT cases, and negative controls
were used. T. b. gambiense HAT cases were defined as patients who were positive by CATT
and positive by any of the microscopy methods in routine use. T. b. rhodesiense HAT cases
were defined as positive by any of the microscopy methods in routine use. Controls were nega-
tive by CATT (for samples collected in T. b. gambiense endemic regions) and by microscopy.
For the first round of screening, serum samples from 40 T. b. gambiense HAT cases (col-
lected between 2002 and 2004) and 60 controls (including 50 samples collected in 2004 from
HAT endemic regions and 10 from European donors) were supplied by the Institute of Tropi-
cal Medicine (ITM, Antwerp, Belgium). Serum samples from 10 T. b. rhodesiense HAT cases
collected between 1990 and 2003 in Uganda were supplied by the National Livestock Resources
Research Institute (NALIRRI, Tororo, Uganda); due to logistical challenges, these samples
were thawed during transport and arrived at Microcoat at room temperature. For the second
round, the same controls were used as in the first round, while NALIRRI supplied new sera
from 35 T. b. gambiense HAT (collected in Uganda between 1998 and 2006) and 20 T. b. rhode-
siense HAT cases (collected in Uganda between 2003 and 2008). Western blot and probing
with an anti-human IgG conjugate revealed that nine of the T. b. gambiense HAT samples that
were obtained from NALIRRI for the second round were significantly degraded, but these
were kept in the study. The third round of screening was carried out using serum samples that
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Table 1. Antigens that were screened in this study.
Antigen name (abbreviation) Source Supplier Reference
Phosphofructokinase (PFK) Trypanosoma brucei brucei Christian de Duve Institute [9]
Fructose-1, 6-bisphosphate aldolase (ALD) Trypanosoma brucei Christian de Duve Institute [10]
Triosephosphate isomerase (TIM) Trypanosoma brucei Christian de Duve Institute [11]
Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH)
Trypanosoma brucei Christian de Duve Institute [12]
Phosphoglycerate kinase (PGK) Trypanosoma brucei Christian de Duve Institute [13]
Phosphoglycerate mutase (PGAM) Trypanosoma brucei Christian de Duve Institute [14]
Enolase (ENO) Trypanosoma brucei Christian de Duve Institute [15]
Glucose-6-phosphate dehydrogenase (G6PDH) Trypanosoma brucei Christian de Duve Institute [16]
Fructose-1,6-bisphosphatase (FBPase) Trypanosoma brucei Christian de Duve Institute [17]
GM6 (GM6) Trypanosoma brucei International Livestock Research Institute [18]
Glutathione S-transferase P1 (GSTP1) Human University of Geneva [19]
Invariant Surface Glycoprotein 64–1 (ISG64) Trypanosoma brucei University of Cambridge [20]
Invariant Surface Glycoprotein 65–1 (ISG65) Trypanosoma brucei University of Cambridge [20]
Invariant Surface Glycoprotein 75–1 (ISG75) Trypanosoma brucei University of Cambridge [20]
Serum resistance associated protein (SRA) Trypanosoma brucei
rhodesiense
University of Cambridge [21,22]
Variant Surface Glycoprotein LiTat 1.3 (VSG LiTat
1.3)†
Trypanosoma brucei
gambiense
Institute of Tropical Medicine [23]
Variant Surface Glycoprotein LiTat 1.5 (VSG LiTat
1.5)†
Trypanosoma brucei
gambiense
Institute of Tropical Medicine [23]
6-phosphogluconate dehydrogenase (6PGDH) Trypanosoma brucei University of Glasgow [24]
Primase small subunit (PriS) Trypanosoma brucei University of Glasgow [25]
Rad51-4 Trypanosoma brucei University of Glasgow [26]
Calreticulin delta (1–25) (CRT-D) Trypanosoma cruzi University of Leicester [27]
Calreticulin R-domain (CRT-R) Trypanosoma cruzi University of Leicester [27]
Rhodesain/TbrCatL Trypanosoma brucei
rhodesiense
University of California [28]
Ornithine decarboxylase (ODC) Trypanosoma brucei University of Texas Southwestern Medical
Center
[29]
S-adenosylmethionine decarboxylase
(AdoMetDC)
Trypanosoma brucei University of Texas Southwestern Medical
Center
[29,30]
Dihydroorotate dehydrogenase (DHODH) Trypanosoma brucei University of Texas Southwestern Medical
Center
[31]
γ-glutamylcystein synthetase (GCS) Trypanosoma brucei University of Texas Southwestern Medical
Center
[29]
Acyl-coA binding protein (ACBP) Trypanosoma brucei University of Dundee [32]
70 kilodalton heat shock protein (HSP70) Trypanosoma brucei University of Wisconsin-Madison [33]
Trypanopain/TbbCatL Trypanosoma brucei
gambiense
University of Wisconsin-Madison [34]
Paraflagellar rod protein 2 (PFR2) Trypanosoma brucei University of Bordeaux [35]
Inhibitor of cysteine peptidase (ICP) Trypanosoma brucei University of Glasgow [36]
MARP1* Trypanosoma brucei University of Bern [37]
Tb09.211.1800 (L14-6)* Trypanosoma brucei
rhodesiense
University of Bern Nerima B
(unpublished)
Tb10.70.6570 (16–6)* Trypanosoma brucei
rhodesiense
University of Bern Nerima B
(unpublished)
Except for the native antigens that were purified from rodent infections (†), all others were recombinant antigens produced using an E. coli expression
system. Antigens marked with an asterisk (*) were only included in the third round of screening.
doi:10.1371/journal.pone.0168074.t001
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were collected in 2008 and 2009 from 150 T. b. gambiense HAT cases, 33 T. b. rhodesiense HAT
cases and 143 controls from a T. b. gambiense endemic region, which were obtained from the
HAT Specimen Bank of the WHO.
Serum samples from the HAT Specimen Bank of the WHO were collected after approval by
the WHO Research Ethics Review Committee and written informed consent from all partici-
pants. The samples from HAT endemic countries supplied by ITM were collected in 2004 dur-
ing routine screening of patients by the national HAT control programs of the Democratic
Republic of the Congo (DRC) and of Benin, for which ethical approval or informed consent
was not required. The samples from European donors supplied by ITM were obtained in 2002
from the Red Cross for development of an RDT, and no information about ethical clearance
could be found. The samples from NALIRRI were collected in Uganda between 1990 and
2008, and information about ethical approval for their collection could not be found.
Slot blot
Slot blotting was used to test the reactivity of antigens as this method uses a matrix (nitrocellu-
lose) that is close to the membrane of an RDT and is therefore expected to provide information
that is directly related to the performance of an RDT. One μg of each antigen was transferred
onto a 0.2 μm nitrocellulose membrane (Protran BA 83, Schleicher & Schu¨ll) using a filtration
manifold system (Whatman). The membrane was washed twice with Tris-buffered saline
(TBS) pH 7.6 and incubated in blocking buffer (TBS, 1% PVP, 0.1% Tween 20, 5% bovine
serum albumin) for 1.5 hours at room temperature. The serum sample was diluted 1:250 in
phosphate buffered saline (PBS) supplemented with 5 mg/ml E. coli lysate and left to stand for
30 minutes (15 minutes in the first round of screening) at room temperature. The membrane
was then incubated with the diluted serum for 1 hour at room temperature, and washed 3
times for 5 minutes in TBS-T (TBS supplemented with 0.1% Tween 20). This was followed by
incubation for 30 minutes at room temperature with a goat anti-human IgG (Jackson Immuno
Research Nr. 109-036-098) or IgM (Jackson Immuno Research Nr. 109-035-129) horseradish
peroxidase (HRP) conjugate diluted at 0.01 μg/ml (0.02 μg/ml in the first round of screening)
in blocking buffer. It was then washed 3 times for 5 minutes in TBS-T and 3 times for 5 min-
utes in water. Finally, the membrane was incubated for 3 minutes at 21˚C with precipitating
tetramethylbenzidine (TMB) (Sigma) and washed with water. The resulting reaction bands
were analysed in duplicate using a flatbed scanner and the Tina 2.09 software, and the ratio of
the densitometric value (optical density/mm2) of each reactive band to the background calcu-
lated. The three rounds of testing were performed in 2007, 2008 and 2009, respectively.
ELISA
In addition to slot blot, ELISA testing was included as this method is more suitable in provid-
ing accurate quantitative data. Polystyrene microplates (Nunc MaxiSorp) were coated by add-
ing 120 μl of antigen at a concentration of 10 μg/ml into each well and incubating for 16 hours
at 20˚C without shaking. They were then washed with PBS and incubated with blocking buffer
(2.5% bovine serum albumin, 2.5% casein in PBS) for 1 hour at room temperature with shak-
ing. After pre-incubating with E. coli lysate as described above, 100 μl of a serum sample
diluted 1:250 in PBS was added and incubated for 1 hour at room temperature with shaking.
The plates were washed three times with 300 μl/well of TBS-T, then 100 μl of anti-human IgG
HRP conjugate diluted 1:160,000 in blocking buffer was added and incubated for 30 minutes
at room temperature with shaking. This was followed by three rounds of washing with TBS-T
at 300 μl/well, then 100 μl of TMB was added and incubated for 10 minutes at room tempera-
ture with shaking. The reaction was stopped by adding 50 μl of 1M H2SO4 and incubating for
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1 minute at room temperature with shaking. The optical density was measured at 450 and 690
nm. The antigens were evaluated based on the absolute value of the signal as long as the signal
to noise ratio was above 5:1, and otherwise were recorded as having no reactivity.
Data analysis
An individual cut-off for each antigen and for each method (slot blot or ELISA) was calculated
as the mean value obtained using all the control sera plus two standard deviations. The reactiv-
ity of each antigen was expressed as the percentage of samples from HAT cases for which the
value was above the cut-off. Antigens were analyzed in duplicate, and the mean value recorded.
In addition, Receiver Operating Characteristic (ROC) analysis was performed using the Med-
Calc statistical software (MedCalc Software bvba) to compute the sensitivity and specificity of
each antigen by varying the cut-off. Youden’s index was calculated to evaluate accuracy [38].
Results
The reactivity of 32 antigens against IgG and IgM in samples from HAT cases was evaluated
by slot blotting in the first round of screening (Fig 1). There was a significant difference in the
IgG and IgM reactivity of samples from T. b. gambiense cases. While the three most reactive
antigens to IgG were ISG64 (100%), ISG65 (100%) and VSG LiTat 1.3 (100%), IgM reactivity
was highest to GSTP1 (90%), ALD (85%) and Rad51-4 (85%). The three antigens that per-
formed best with IgG (100%) only ranked 9th, 19th and 28th with IgM. When the 14 best anti-
gens were compared, the percentage reactivity was higher with IgG than with IgM (9% higher
on average).
The results of testing the antigens on T. b. rhodesiense HAT samples are shown in Fig 2.
Two of the antigens that performed best in reactivity to either IgG or IgM (ISG64 and ISG65,
and GSTP1 and ALD, respectively) were also the best on T. b. gambiense HAT samples. The
performance of other less reactive antigens exhibited some differences when the results of the
two sets of HAT sera were compared, although the overall ranking was quite similar. The reac-
tivity was on average higher with T. b. gambiense than with T. b. rhodesiense HAT samples (by
5.1% and 2.7% with IgG and IgM, respectively).
A new set of 18 antigens was included in the second round of screening. These included 14
that in the first round of screening had an IgG reactivity higher than 50% on patient sera, and
4 that were only partially soluble in the first round of screening. As the IgG reactivity to T. b.
gambiense sera in the first round of screening was higher than IgM reactivity, and given that
IgG molecules are more stable and therefore more suitable for developing a diagnostic test
than IgM, subsequent rounds of screening included testing for IgG only. It was also assumed
that detection of IgG would be more suitable in screening for T. b. gambiense HAT due to the
chronic nature of this form of the disease. In addition to slot blots, antigens were also screened
by ELISA in this second round in order to generate quantitative results.
The reactivity of antigens to T. b. gambiense sera was higher using ELISA (Fig 3B) than
by slot blot (Fig 3A), with an average difference of 14%. The three best antigens with both
methods were VSG LiTat 1.3, VSG LiTat 1.5 and ISG64, although their ranking was different.
ISG64 performed best (71%) in ELISA followed by VSG LiTat 1.3 (69%) and VSG LiTat 1.5
(69%), while VSG LiTat 1.3 was the best (60%) in slot blot, followed by VSG LiTat 1.5 (49%)
and ISG64 (40%). Significant differences were observed in the ranking of the other antigens
depending on the test method that was used. For example, while PFK was the fifth best antigen
by slot blot, it was only the 17th by ELISA.
The results of screening antigens on T. b. rhodesiense sera are shown in Fig 4. As observed
with T. b. gambiense sera, the antigens performed differently depending on the test method
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used. Using slot blotting, VSG LiTat 1.3 (80%) had the highest reactivity, followed by SRA
(75%) and VSG LiTat 1.5 (65%). By ELISA, SRA performed best (85%), followed by ISG65
(65%) and ISG64 (60%). The percentage reactivity by slot blot was on average 16.6% higher
with T. b. rhodesiense than with T. b. gambiense cases, which was unlike the observations
obtained in the first round of screening. By contrast, reactivity by ELISA was on average 4.2%
lower with T. b. rhodesiense than with T. b. gambiense sera. SRA was the antigen that exhibited
the greatest difference in reactivity between the two disease forms. While the reactivity of SRA
by slot blot was 75% with T. b. rhodesiense, it was only 17% with T. b. gambiense.
Fig 1. Percentage IgG (A) and IgM (B) reactivity of 32 antigens on sera from T. b. gambiense HAT cases (N = 40) assessed by slot blot
(first round of screening). Antigens are shown in descending order of reactivity. Antigens marked with an asterisk (*) were only partially soluble.
doi:10.1371/journal.pone.0168074.g001
Evaluation of Candidate Antigens for HAT Serological Test
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The third round of screening was carried out using a larger collection of clinical samples, in
order to generate more significant data on the most promising antigens using both slot blot
and ELISA. Thirteen antigens, including 10 that had the highest reactivity on patient sera in
Fig 2. Percentage IgG (A) and IgM (B) reactivity of 32 antigens on sera from T. b. rhodesiense HAT
cases (N = 10) assessed by slot blot (first round of screening). Antigens are shown in descending order
of reactivity. Antigens marked with an asterisk (*) were only partially soluble.
doi:10.1371/journal.pone.0168074.g002
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the second round (results of both slot blot and ELISA combined), and 3 new ones (MARP1,
L14-6 and 16–6) were screened in this round. The 3 new antigens were supplied after the first
two rounds of screening had been completed. Fig 5 illustrates that when the antigens were
screened using T. b. gambiense sera, the three best antigens using both tests were the same as in
Fig 3. Percentage IgG reactivity of 18 antigens on sera from T. b. gambiense HAT cases (N = 35)
assessed by slot blot (A) and by ELISA (B) (second round of screening). Antigens are shown in
descending order of reactivity.
doi:10.1371/journal.pone.0168074.g003
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the second round. Using slot blot, VSG LiTat 1.3 performed best (91%) followed by VSG
LiTat 1.5 (81%) and ISG64 (70%), while by ELISA, VSG LiTat 1.5 was first (92%) followed by
VSG LiTat 1.3 (82%) and ISG64 (48%). The next three antigens behaved in a similar manner
Fig 4. Percentage IgG reactivity of 18 antigens on sera from T. b. rhodesiense HAT cases (N = 10)
assessed by slot blot (A) and by ELISA (B) (second round of screening). Antigens are shown in
descending order of reactivity.
doi:10.1371/journal.pone.0168074.g004
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with both tests, but in a different order. Using slot blot, ISG65 (37%) was followed by GM6
(28%) and ISG75 (24%), while by ELISA, GM6 (28%) was followed by ISG65 (25%) and ISG75
(9%).
Fig 5. Percentage IgG reactivity of 13 antigens on sera from T. b. gambiense HAT cases (N = 150)
assessed by slot blot (A) and by ELISA (B) (third round of screening). Antigens are shown in descending
order of reactivity.
doi:10.1371/journal.pone.0168074.g005
Evaluation of Candidate Antigens for HAT Serological Test
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When the antigens were screened using T. b. rhodesiense sera, the three best antigens were
the same ones irrespective of the test used (Fig 6). These were also the same antigens as
observed in the second round of screening by slot blotting. According to slot blotting, VSG
Fig 6. Percentage IgG reactivity of 13 antigens on sera from T. b. rhodesiense HAT cases (N = 33)
assessed by slot blot (A) and by ELISA (B) (third round of screening). Antigens are shown in descending
order of reactivity.
doi:10.1371/journal.pone.0168074.g006
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LiTat 1.5 (45%) was followed by VSG LiTat 1.3 (39%) and SRA (39%). By ELISA, SRA per-
formed best (39%), followed by VSG LiTat 1.3 (33%) and VSG LiTat 1.5 (27%). In a similar
manner to what was observed when the results of the first round of screening were compared,
the average percentage reactivity by slot blot and by ELISA was higher with T. b. gambiense
than with T. b. rhodesiense sera, with differences of 11.2% and 10.1%, respectively.
ROC analysis of the results obtained by ELISA shows that among the 13 antigens in the
third round of screening, the highest accuracy for T. b. gambiense was achieved using VSG
LiTat 1.5 (93%), followed by VSG LiTat 1.3 (79%) and ISG64 (67%) (Table 2). This analysis
also indicates that if a sensitivity of 90% is considered to be acceptable, using VSG LiTat 1.5
would result in a specificity as high as 98%. Conversely, if specificity is set at 90%, a sensitivity
of 97% can be reached with this antigen. VSG LiTat 1.3 could also be used to develop a test
with a high specificity, but due to the lower accuracy of this antigen, there would be a stronger
trade-off in sensitivity. For example, a specificity of 97% could be achieved using VSG LiTat
1.3 with a sensitivity of 70%. Using the less accurate ISG64 antigen would only result in a spec-
ificity of 91% with a sensitivity of 70%.
With T. b. rhodesiense samples, ROC analysis of the results obtained using ELISA shows
that among the 13 antigens of the third round of screening, the highest accuracy was achieved
with SRA (56%), followed by VSG LiTat 1.3 (43%) and VSG LiTat 1.5 (39%) (Table 3). This
analysis also indicates that if a sensitivity of 90% is targeted, using SRA would only result in a
specificity of 33%. Conversely, if specificity is set at 90%, a sensitivity of 61% can be reached
with this antigen. Using VSG LiTat 1.3 would not be appropriate to develop a test with a high
specificity, even with a strong trade-off in sensitivity. For example, a specificity of only 73%
could be achieved using VSG LiTat 1.3 with a sensitivity of 70%. Using the less accurate VSG
LiTat 1.5 antigen would result in a specificity of only 64% with a sensitivity of 70%.
While the performance of some antigens in detecting T. b. gambiense HAT was very prom-
ising, combining two antigens in one test could theoretically result in a diagnostic sensitivity
Table 2. ROC analysis of the reactivity of 13 antigens on sera from T. b. gambiense HAT cases (N = 150) and controls (N = 143) assessed by ELISA
(third study round).
VSG LiTat
1.5
VSG LiTat
1.3
ISG64 GM6 ISG65 ISG75 SRA HSP70 MARP1 GAPDH PFK L14-6 16–6
Maximum
accuracy
Youden’s index
(%)
93 79 67 47 47 34 25 22 10 6 NA NA NA
Sensitivity (%) 96 90 85 77 81 75 68 83 91 14 NA NA NA
Specificity (%) 97 89 81 70 65 59 57 39 19 92 NA NA NA
Specificity
(%)
100 Sensitivity (%) 37 47 3 0 0 1 1 0 0 1 NA NA NA
90 Sensitivity (%) 97 87 71 40 45 19 23 20 8 14 NA NA NA
80 Sensitivity (%) 98 93 87 61 63 36 43 36 20 19 NA NA NA
70 Sensitivity (%) 98 97 91 77 73 59 49 49 29 31 NA NA NA
Sensitivity
(%)
100 Specificity (%) 3 29 47 3 11 5 0 3 3 0 NA NA NA
90 Specificity (%) 98 89 72 31 52 41 33 28 19 18 NA NA NA
80 Specificity (%) 98 95 85 58 67 54 39 39 29 18 NA NA NA
70 Specificity (%) 99 97 91 75 76 65 53 51 33 41 NA NA NA
For each antigen, theoretical test performance was assessed by calculating Youden’s index, sensitivity and specificity using a cut-off that results in the
maximum accuracy (maximum Youden’s index). The sensitivity obtained by setting a cut-off corresponding to a specificity of 100%, 90%, 80% and 70%, as
well as the specificity obtained by setting a cut-off corresponding to a sensitivity of 100%, 90%, 80% and 70% are also indicated. NA: values that could not
be computed by the software.
doi:10.1371/journal.pone.0168074.t002
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that is even higher. The results obtained in the third round of screening of 13 antigens were
used to compute 78 possible antigen pairs that could be used to develop hypothetical tests. A
combination of VSG LiTat 1.3, which detected 91% of the T. b. gambiense sera (Fig 3A) and
ISG75 resulted in the highest reactivity (97%) using slot blot (Table 4 and S1 Table). This was
followed by VSG LiTat 1.3 combined with ISG64 (95%) and by VSG LiTat 1.3 combined with
either GM6 or VSG LiTat 1.5 (93%). Using ELISA (S2 Table), the best antigen pair to detect T.
b. gambiense sera was VSG LiTat 1.5 and VSG LiTat 1.3 (95%), followed by VSG LiTat 1.5 and
16–6 (94%), and by VSG LiTat 1.5 combined with either GM6 or ISG64 (93%). The reactivity
of these pairs in ELISA was higher than using VSG LiTat 1.5 alone (92%, Fig 3B).
A combination of antigens also resulted in a stronger reactivity on T. b. rhodesiense sera.
Reactivity increased to 67% when SRA was combined with either VSG LiTat 1.3 or VSG LiTat
Table 3. ROC analysis of the reactivity of 13 antigens on sera from T. b. rhodesiense HAT cases (N = 33) and controls (N = 143) assessed by ELISA
(third round of screening).
SRA VSG LiTat
1.3
VSG LiTat
1.5
ISG65 ISG75 GM6 ISG64 16–6 MARP1 HSP70 PFK GAPDH L14-6
Maximum
accuracy
Youden’s index
(%)
56 43 39 30 29 27 25 21 12 8 7 NA NA
Sensitivity (%) 76 70 79 76 85 48 45 30 42 18 33 NA NA
Specificity (%) 81 73 61 55 44 79 79 91 70 89 73 NA NA
Specificity
(%)
100 Sensitivity (%) 15 15 3 0 3 0 3 3 0 0 0 NA NA
90 Sensitivity (%) 61 39 36 27 12 36 27 30 12 18 12 NA NA
80 Sensitivity (%) 76 58 48 42 39 42 45 33 30 18 24 NA NA
70 Sensitivity (%) 79 70 55 55 55 48 45 45 42 33 33 NA NA
Sensitivity
(%)
100 Specificity (%) 19 0 8 5 5 3 6 0 1 0 0 NA NA
90 Specificity (%) 33 17 35 11 28 9 16 8 15 14 1 NA NA
80 Specificity (%) 71 55 61 45 45 27 27 21 30 14 21 NA NA
70 Specificity (%) 82 73 64 57 54 31 41 33 37 28 37 NA NA
For each antigen, Youden’s index, sensitivity and specificity are shown using a cut-off that results in the maximum accuracy (maximum Youden’s index).
The sensitivity obtained by setting a cut-off corresponding to a specificity of 100%, 90%, 80% and 70%, as well as the specificity obtained by setting a cut-off
corresponding to a sensitivity of 100%, 90%, 80% and 70% are also indicated. NA: values that could not be computed by the software.
doi:10.1371/journal.pone.0168074.t003
Table 4. Percentage IgG reactivity of the five most reactive antigen pairs as well as the five most reactive individual antigens on sera from T. b.
gambiense HAT cases (N = 150) and T.b. rhodesiense HAT cases (N = 33) assessed by slot blot (third round of screening).
Antigen pair/ antigen T. b. gambiense reactivity (%) Antigen pair/ antigen T. b. rhodesiense reactivity (%)
VSG LiTat 1.3 & ISG75 97 VSG LiTat 1.3 & SRA 67
VSG LiTat 1.3 & ISG64 95 VSG LiTat 1.5 & SRA 67
VSG LiTat 1.3 & GM6 93 VSG LiTat 1.5 & ISG64 55
VSG LiTat 1.5 & VSG LiTat 1.3 93 MARP1 & VSG LiTat 1.5 55
MARP1 & VSG LiTat 1.3 92 VSG LiTat 1.3 & ISG64 52
VSG LiTat 1.3 91 VSG LiTat 1.5 45
VSG LiTat 1.5 81 VSG LiTat 1.3 39
ISG64 70 SRA 39
ISG65 37 ISG64 18
GM6 28 16–6 18
Antigen pairs and individual antigens are shown in descending order of reactivity.
doi:10.1371/journal.pone.0168074.t004
Evaluation of Candidate Antigens for HAT Serological Test
PLOS ONE | DOI:10.1371/journal.pone.0168074 December 9, 2016 14 / 23
1.5 in slot blot (Table 4 and S3 Table), and to 61% when SRA was combined with either GM6
or VSG LiTat 1.3 in ELISA (S4 Table). These were significant improvements when compared
to the reactivity of the best single antigens, which were VSG LiTat 1.5 (45%) and SRA (39%) in
slot blot and ELISA respectively.
Discussion
This study comprised the first systematic, independent assessment of the diagnostic potential
of a large panel of antigens that could potentially be used for development of a rapid diagnostic
test (RDT) for HAT. Since this work was completed, a number of RDTs have actually been
developed, and are briefly discussed below. A number of very promising antigens were identi-
fied, both for gambiense and for rhodesiense HAT. While there were many similarities in the
results of the three rounds of screening, there were also a number of important differences,
both in the ranking of antigens and in their absolute reactivity. The reactivity of the best anti-
gens was significantly higher in the first and third rounds than in the second round, and differ-
ences between antigens were also more pronounced in the third round. These differences
between study rounds might be explained by two factors. First, the sample size was signifi-
cantly larger in the third round compared to other rounds, which enabled more accurate mea-
surements. Second, the clinical samples used in the first and second rounds had been stored
for lengthy periods, during which they could have gone through multiple unknown cycles of
freezing and thawing, which could have caused some loss of immunoreactivity. Significant
degradation was in fact observed in some of the samples that were supplied for the second
round. This may have resulted in a biased assessment of the reactivity of some antigens and
possibly exclusion of some of them from subsequent rounds. By contrast, samples used in the
third round were collected recently, and subjected to a maximum of two rounds of freezing
and thawing. Therefore, results from the third round of testing should be considered as a more
reliable indicator of the reactivity of antigens. Also, results obtained with gambiense samples
are likely to be more reliable than those obtained with rhodesiense, as they were based on a
much larger sample set.
The antigens that were most reactive were proteins that are known to be localized extracel-
lularly, on the surface of parasites, which may explain why strong immunoreactivity was
observed in plasma samples from infected patients. In particular, VSG LiTat 1.3 and VSG
LiTat 1.5, which belong to the group of VSGs that cover the external surface of the bloodstream
form of T. brucei [39], were found to be the two most reactive antigens against gambiense sam-
ples, and among the three most reactive antigens against rhodesiense samples. Noteworthy, T.
b. gambiense clones expressing these VSGs were also among the most sensitive for detecting
gambiense patients using immune trypanolysis [40]. However, VSGs have been reported to
exhibit some heterogeneity in their expression among parasite isolates, and could therefore
present a risk in terms of sensitivity if they are included in a diagnostic test. In particular, the
gene encoding VSG LiTat 1.3 was found to be absent in some T. b. gambiense isolates from
Cameroon [41]. Other surface proteins such as ISG64, ISG65 and to a lesser extent ISG75 were
also quite reactive, especially to samples from gambiense patients. In contrast, proteins that are
known to be intracellular, and therefore less accessible to the host’s immune system, exhibited
a very low reactivity. These include enzymes of the glycolytic pathway (GAPDH and PFK), a
cytoskeleton-associated protein (MARP1), a pyrimidine biosynthetic enzyme (DHODH) and
a chaperone (HSP70). However, there were also exceptions to this perhaps over-simplistic dis-
tinction. In particular, SRA exhibited a strong reactivity to rhodesiense samples, although it has
been shown to be an intracellular protein localized to the lysosome and the endocytic pathway
[42]. It is also possible that the observed reactivity of SRA would relate to cross-reacting
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antibodies that were actually generated against VSGs, since SRA is closely related to VSGs
[43]. In addition, GM6, which is located on flagellum attachment zone fibres connecting
microtubules to the flagellum [18], was moderately reactive to gambiense samples. While they
may not be very useful for serodiagnosis, some of the intracellular proteins that were tested in
this study might have utility as a means to detect response to therapy when parasites are lysed
after cidal effects of drug treatment. The fact that the human protein GSTP1 exhibited signifi-
cant reactivity to both gambiense and rhodesiense samples might be explained by non-specific
activation of B lymphocytes, which has been reported to occur during trypanosomal infections
in mice and in cattle [44–47]. This phenomenon might also be responsible for the significant
reactivity of SRA to gambiense samples that was found in this study.
The chronic nature of gambiense HAT could provide an explanation for the observation
that IgG reactivity was on average higher with gambiense than with rhodesiense samples, as
patients infected with T. b. gambiense are likely to have been diagnosed and sampled after a sig-
nificantly longer infection time than in the case of the more acute T. b. rhodesiense infections.
On the other hand, rhodesiense patients may not have had sufficient time to mount a strong
IgG response comparable to that observed in gambiense patients. The fact that the difference
in reactivity between the two forms of the disease was less pronounced in the case of IgM is
consistent with this explanation, as IgM production occurs earlier in infections, and large
amounts of this class of antibody may be produced prior to diagnosis of gambiense or rhode-
siense patients. An alternative explanation for this less pronounced difference could be the gen-
erally lower specificity of IgM in comparison to IgG antibodies.
The reactivity values obtained in the three rounds using a fixed cut-off (mean reactivity of
controls plus 2 standard deviations) correspond to sensitivity values that would theoretically
be obtained with a test that is calibrated as having a specificity of 95.4%, assuming a normal
distribution [48]. The ROC analysis that was performed in the third round allowed better
appreciation of the full diagnostic potential of antigens by calculating the accuracy and the
relationship between sensitivity and specificity of each antigen. Although the ranking of anti-
gens according to accuracy (Youden’s index) was very similar to that obtained with a fixed
cut-off by ELISA, this ROC analysis provides additional information and shows that using the
same antigen, tests with very different diagnostic properties could be developed. For example,
using VSG LiTat 1.5 on gambiense samples, a test that is highly specific (98%) but moderately
sensitive (90%) could be developed, as well as a test that is highly sensitive (97%) but moder-
ately specific (90%). Therefore, information on the intended use of a test, including the target
population, disease incidence, setting, diagnostic algorithm as well as available treatments, will
need to be considered carefully when defining target specifications to be achieved in test devel-
opment using these antigens.
As no single antigen assessed in this study reacted with all the positive sera, combining two
or more antigens might be necessary in order to develop a test with a sensitivity that would be
sufficiently high for effective disease control and elimination. An example is a combination of
VSG LiTat 1.3 and VSG LiTat 1.5, which performed best by slot blot on T. b. gambiense sera.
Since slot blot uses a nitrocellulose matrix that is similar to that used in RDTs, these antigens
were considered as the best candidates for developing an RDT. Indeed, since this study was
carried out, two RDTs for gambiense HAT have been developed and commercialized, both
using these two antigens. One is the HAT Sero-K-SeT manufactured by Coris BioConcept
(Belgium), with a reported sensitivity of 93.9% and a specificity of 99.0% using archived sera
[23], as well as a sensitivity of 98.5% and a specificity of 98.6% in a prospective passive screen-
ing trial [49]. The other is the SD BIOLINE HAT produced by Alere/Standard Diagnostics
(South Korea). A study that compared the performance of these two RDTs on stored plasma
originating from Guinea and Coˆte d’Ivoire reported sensitivities of 99.1% and 99.6%, and
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specificities of 88.3% and 87.9% for the HAT Sero-K-SeT and the SD BIOLINE HAT, respec-
tively [50]. A prototype version of the SD BIOLINE HAT was also evaluated in a prospective
study in Angola, the DRC and the Central African Republic [51], without pre-selecting partici-
pants using CATT. This study concluded that the sensitivity of the RDT was not statistically
different from the sensitivity of CATT when performed on whole blood, while its specificity
was 1.3% lower than that of CATT. Taken together, these results demonstrate that the method-
ology that we used in the present study was appropriate in identifying antigens with a high
potential for development of an RDT for HAT.
Most of the antigens were found to react to both gambiense and rhodesiense infections, and
the antigens that exhibited a strong reactivity with samples from one form of the disease were
also reactive to the other form. These results are consistent with the extremely high level of
genomic similarity that has been reported between T. b. gambiense and T. b. rhodesiense
[52,53]. SRA was an exception, since this antigen was much more reactive to rhodesiense than
to gambiense samples. This finding is in agreement with the fact that SRA is a protein that is
only expressed by T. b. rhodesiense and not by T. b. gambiense [21,22]. Although developing an
RDT that would detect both forms of disease using some of the antigens included in this panel
could be considered, it seems that even if two antigens are combined, the resulting sensitivity
for rhodesiense would not be sufficiently high. Further research is therefore necessary to iden-
tify other antigens for use in developing a test for rhodesiense HAT. One approach might be to
evaluate the diagnostic potential of the 254 proteins that were identified by Eyford et al. [54] in
the plasma from patients infected with T. b. rhodesiense. Although gambiense and rhodesiense
HAT are found in discrete geographical foci [55], there have been concerns that the two dis-
ease forms may eventually coexist in the same region. In particular, outbreaks of rhodesiense
HAT in previously unaffected districts of Uganda resulted in a significant expansion of the
rhodesiense HAT endemic region from the southeast towards the northwestern region of the
country, posing a risk of overlap with the other disease form [56]. In such an event, an RDT
that would be specific for T. b. rhodesiense infections would be very useful, since treatments
differ between the two disease forms [57]. It would also be worth testing samples from rhode-
siense patients with the RDTs that have been developed for gambiense HAT, as these tests
might also prove useful as screening tools for this form of disease. Moreover, it would be inter-
esting to assess the diagnostic potential of the T. b. gambiense-specific TgsGP protein [58,59],
which was not available for inclusion in this study.
The results from the second and third rounds of screening were obtained using two different
and complementary methods. Assessment by slot blotting gives an indication of the perfor-
mance of antigens on a nitrocellulose membrane, which is a commonly used solid phase plat-
form in lateral-flow RDTs. On the other hand, ELISA relies on photometric measurements that
should allow for a more precise quantification of the reactivity of antigens. Although there were
some differences in the ranking of antigens using these two methods, the overall pattern of
results for both slot blotting and ELISA was remarkably similar, reinforcing the validity of the
results generated in this study. However, some differences in reactivity were found using these
two methods. For instance, ISG75 and GAPDH exhibited a much higher reactivity in slot blot
than in ELISA. Although the reasons for such differences were not investigated, binding proper-
ties of different antigens to the two matrices are likely to play a role, which may result in distinct
affinity as well as different orientation or denaturation of antigens. When interpreting these
results, it is therefore critical to also take into account the matrix on which the antigens would
eventually be applied in a serological test. In our case, the target was to develop an RDT with a
nitrocellulose matrix, and therefore the slot blot results were given higher consideration.
While efforts were made to be as comprehensive as possible and include all the antigens
that had been previously reported as having a diagnostic potential, this work only included 35
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antigens. It is possible that other antigens that were either not included or had not been identi-
fied at that time could perform equally well or better than assessed in the present study. For
example, the flagellar calcium-binding protein TB-17 [20,60], the Gene Related to Expression
Site Associated Gene (GRESAG) 4, and transferrin receptor subunits ESAG 6 and 7 have also
been suggested as potential candidates [20]. Since the most reactive antigens include the native
VSG LiTat 1.3 and VSG LiTat 1.5 antigens, which are costly and difficult to produce, one
approach might be to generate recombinant versions of these proteins. This was attempted by
Roge´ et al. [61], who expressed the immunogenic N-terminal part of these antigens in Pichia
pastoris, and by Rooney et al. [62], who expressed these antigens and ISG65 in Leishmania tar-
entolae. While evaluation of these recombinant antigens by ELISA gave very promising results,
their diagnostic potential in an RDT format remains to be confirmed. Another approach has
been to produce synthetic peptide mimotopes corresponding to epitopes of VSG LiTat 1.3 and
VSG LiTat 1.5; however, the diagnostic accuracy of these peptides was found to be lower than
that of full-length native antigens [63–65].
An important limitation of this study was in the selection of the clinical samples that were
used to screen the antigens. All gambiense HAT cases were identified following screening
using the CATT test. CATT reagents consist of lyophilized bloodstream form T. b. gambiense
parasites expressing VSG LiTat 1.3 [4]. This means that by definition, all samples from gam-
biense HAT cases were sero-reactive to VSG LiTat 1.3. This selection bias could explain why
this antigen performed so well in this study. In addition, it is conceivable that samples from
other gambiense HAT cases with a different serological profile and that would potentially be
more reactive to other antigens could have been missed during screening with CATT. Simi-
larly, all controls originating from gambiense endemic countries had to be negative with
CATT. This is likely to have introduced a bias resulting in an over-estimate of the specificity of
antigens that are related to CATT, such as VSG LiTat 1.3. It is therefore possible that the results
of this study could have been significantly different if samples had not been pre-selected using
any serological test. Unfortunately, we could not get access to samples that were not pre-
selected by CATT, since virtually all the prospective studies involving sample collection that
have been conducted over the last few decades involved selection of participants on the basis
of CATT results. Future attempts to evaluate antigens for their potential in diagnosis of HAT
would benefit from new prospective collections of clinical samples whose selection would not
rely on serological tests, but which could take advantage of new diagnostic tools, such as the
molecular detection tests that have recently been made available [66].
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